You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: February 19, 2020

DrugPatentWatch Database Preview

Patent: 10,338,039

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,338,039

Title:	Method for detecting monoclonal antibody using mass spectrometry
Abstract:	A method is provided for more easily detecting and quantifying a protein by regioselectively digesting a variable region of an Fab domain of a monoclonal antibody while suppressing proteolysis of an Fc domain. In the method, a porous body in which a monoclonal antibody is immobilized in pores and nanoparticles on which a protease is immobilized are brought into contact with each other in a liquid to perform selective proteolysis of the monoclonal antibody, and a resulting peptide fragment is detected using liquid chromatography-mass spectrometry (LC-MS), and a peptide having an amino acid sequence that includes an amino acid derived from a CDR2 region of a heavy chain or a light chain of the monoclonal antibody is detected.
Inventor(s):	Shimada; Takashi (Kyoto, JP), Iwamoto; Noriko (Kyoto, JP)
Assignee:	SHIMADZU CORPORATION (Kyoto-shi, JP)
Application Number:	15/556,018
Patent Claims:	see list of patent claims

Details for Patent 10,338,039

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26	Start Trial	SHIMADZU CORPORATION (Kyoto-shi, JP)	2035-03-09	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	002	1997-11-26	Start Trial	SHIMADZU CORPORATION (Kyoto-shi, JP)	2035-03-09	RX		search
Genentech	HERCEPTIN	trastuzumab	VIAL; INTRAVENOUS	103792	001	1998-09-25	Start Trial	SHIMADZU CORPORATION (Kyoto-shi, JP)	2035-03-09	RX	Orphan	search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	Start Trial	SHIMADZU CORPORATION (Kyoto-shi, JP)	2035-03-09	RX	Orphan	search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	002	2004-02-26	Start Trial	SHIMADZU CORPORATION (Kyoto-shi, JP)	2035-03-09	RX	Orphan	search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 10,338,039

Subscribe to access the full database, or Start Trial
Country	Patent Number	Publication Date
Brazil	112017017854	Apr 10, 2018
China	107407666	Nov 28, 2017
European Patent Office	3270154	Jan 09, 2019
European Patent Office	3270154	Jan 17, 2018
Japan	6428911	Nov 28, 2018
>Country	>Patent Number	>Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Medtronic

Express Scripts

Merck

Dow

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.